Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Phone609-359-3020
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$63.55 million
Profitability
Miscellaneous
Employees165
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable
Antares Pharma (NASDAQ:ATRS) Frequently Asked Questions
What is Antares Pharma's stock symbol?
Antares Pharma trades on the NASDAQ under the ticker symbol "ATRS."
How were Antares Pharma's earnings last quarter?
Antares Pharma Inc (NASDAQ:ATRS) released its quarterly earnings data on Tuesday, November, 5th. The specialty pharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.02) by $0.03. The specialty pharmaceutical company earned $34.31 million during the quarter, compared to analysts' expectations of $26.36 million. Antares Pharma had a negative return on equity of 1.40% and a negative net margin of 0.56%. View Antares Pharma's Earnings History.
When is Antares Pharma's next earnings date?
What price target have analysts set for ATRS?
3 Wall Street analysts have issued 12-month target prices for Antares Pharma's stock. Their forecasts range from $1.99 to $5.65. On average, they expect Antares Pharma's share price to reach $4.05 in the next twelve months. This suggests that the stock has a possible downside of 6.1%. View Analyst Price Targets for Antares Pharma.
What is the consensus analysts' recommendation for Antares Pharma?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Antares Pharma in the last year. There are currently 2 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Antares Pharma.
Has Antares Pharma been receiving favorable news coverage?
News stories about ATRS stock have been trending very negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Antares Pharma earned a news impact score of -3.0 on InfoTrie's scale. They also gave headlines about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Antares Pharma.
Are investors shorting Antares Pharma?
Antares Pharma saw a decline in short interest during the month of October. As of October 31st, there was short interest totalling 4,040,000 shares, a decline of 10.0% from the September 30th total of 4,490,000 shares. Based on an average daily trading volume, of 994,700 shares, the short-interest ratio is presently 4.1 days. Approximately 2.7% of the company's shares are sold short. View Antares Pharma's Current Options Chain.
Who are some of Antares Pharma's key competitors?
Some companies that are related to Antares Pharma include Align Technology (ALGN), Cooper Companies (COO), DENTSPLY SIRONA (XRAY), West Pharmaceutical Services (WST), Haemonetics (HAE), ICU Medical (ICUI), Neogen (NEOG), Quidel (QDEL), STAAR Surgical (STAA), Merit Medical Systems (MMSI), Atrion (ATRI), Anika Therapeutics (ANIK), Cerus (CERS), OraSure Technologies (OSUR) and Utah Medical Products (UTMD).
What other stocks do shareholders of Antares Pharma own?
Who are Antares Pharma's key executives?
Antares Pharma's management team includes the folowing people:
- Mr. Robert F. Apple, CEO, Pres & Director (Age 53)
- Mr. Fred M. Powell, Exec. VP & CFO (Age 58)
- Mr. Peter J. Graham, Exec. VP of HR, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 52)
- Dr. James Patrick Tursi, EVP, Head of R&D & Chief Medical Officer (Age 54)
- Mr. Keith Muckenhirn, Principal Accounting Officer, VP of Fin. & Corp. Controller (Age 56)
Who are Antares Pharma's major shareholders?
Antares Pharma's stock is owned by a number of of retail and institutional investors. Top institutional investors include Sargent Investment Group LLC (2.04%), State of New Jersey Common Pension Fund D (0.47%), Perkins Capital Management Inc. (0.19%), California Public Employees Retirement System (0.16%), Monarch Partners Asset Management LLC (0.10%) and Envestnet Asset Management Inc. (0.03%). Company insiders that own Antares Pharma stock include Jacques Gonella, Leonard S Jacob, Robert F Apple and Thomas J Garrity. View Institutional Ownership Trends for Antares Pharma.
Which major investors are selling Antares Pharma stock?
ATRS stock was sold by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc. and SG Americas Securities LLC. Company insiders that have sold Antares Pharma company stock in the last year include Jacques Gonella, Leonard S Jacob and Thomas J Garrity. View Insider Buying and Selling for Antares Pharma.
Which major investors are buying Antares Pharma stock?
ATRS stock was purchased by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, Sargent Investment Group LLC, Monarch Partners Asset Management LLC, California Public Employees Retirement System, Russell Investments Group Ltd., Cadence Capital Management LLC, CWM LLC and Envestnet Asset Management Inc.. View Insider Buying and Selling for Antares Pharma.
How do I buy shares of Antares Pharma?
Shares of ATRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Antares Pharma's stock price today?
One share of ATRS stock can currently be purchased for approximately $4.31.
How big of a company is Antares Pharma?
Antares Pharma has a market capitalization of $703.52 million and generates $63.55 million in revenue each year. The specialty pharmaceutical company earns $-6,510,000.00 in net income (profit) each year or ($0.04) on an earnings per share basis. Antares Pharma employs 165 workers across the globe.View Additional Information About Antares Pharma.
What is Antares Pharma's official website?
How can I contact Antares Pharma?
Antares Pharma's mailing address is 100 PRINCETON SOUTH SUITE 300, EWING NJ, 08628. The specialty pharmaceutical company can be reached via phone at 609-359-3020 or via email at [email protected]
MarketBeat Community Rating for Antares Pharma (NASDAQ ATRS)
MarketBeat's community ratings are surveys of what our community members think about Antares Pharma and other stocks. Vote "Outperform" if you believe ATRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
